Business
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
– Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of
About this update from Agios Pharmaceuticals, Inc.
[{"type":"text","content":"– Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis – – New Data from Two Investigator Sponsored Studies of Mitapivat in Sickle Cell Disease Continue to Support Advancement to Pivotal Development – – First Data from the Phase 1 Healthy Volunteer Study of AG-946 Show Dose-dependent Changes in ATP and 2,3-DPG – – Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that a broad set of clinical and translational data from its genetically defined disease programs in chronic hemolytic anemias, including pyruvate kinase (PK) deficiency, thalassemia and sickle cell disease, will be presented at the American Society of Hematology (ASH) Annual Meeting & Exposition, to be held Dec. 11-14, 2021, virtually and in person in Atlanta. In total, eight abstracts led by Agios will be presented, as well as five abstracts led by external collaborators. The accepted abstracts are listed below and are available online on the ASH conference website: https://www.hematology.org/meetings/annual-meeting/abstracts. Presentations by Agios Oral Presentations: Title: Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-transfusion-dependent Alpha- or Beta-Thalassemia Presentation Time: Monday, Dec. 13, 2021, at 11:45 a.m. ETOral Abstract Session: 112. Thalassemia and Globin Gene RegulationAbstract: 576Presenter: Kevin H. M. Kuo, M.D., Division of Hematology, University of Toronto, Toronto, Canada Title: Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained Over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-term Extension StudyPresentation Time: Monday, Dec. 13, 2021, at 6:30 p.m. ETOral Abstract Session: 101. Red Cells and Erythropoiesis, Excluding Iron: Normal and Perturbed ErythropoiesisLocation: Georgia World Congress Center, B401-B402Abstract: 848Presenter: Rachael Grace, M.D., MMSc, Dana-Farber/Boston Children's Cancer and Blood Disorders Center Poster Presentations:Title: Bone Mineral Density Remains Stable in Pyruvate Kinase Def...